Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Aug 16, 2023 7:30am EDT

Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Aug 14, 2023 8:00am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update

Jul 31, 2023 9:00am EDT

Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference

Jun 28, 2023 8:00am EDT

Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement

Jun 23, 2023 8:00am EDT

Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy

Jun 20, 2023 8:00am EDT

Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab

May 10, 2023 7:30am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update

Apr 18, 2023 4:01pm EDT

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 17, 2023 8:00am EDT

Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting

Mar 14, 2023 4:31pm EDT

Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting

1...
2
3
4
5
6
7
8
9
10
11
...13